Chesley Taft & Associates LLC Buys 507 Shares of Johnson & Johnson (NYSE:JNJ)

Chesley Taft & Associates LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 208,555 shares of the company’s stock after buying an additional 507 shares during the period. Johnson & Johnson comprises approximately 1.7% of Chesley Taft & Associates LLC’s portfolio, making the stock its 14th largest position. Chesley Taft & Associates LLC’s holdings in Johnson & Johnson were worth $32,991,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the business. Dempze Nancy E boosted its position in Johnson & Johnson by 0.7% during the third quarter. Dempze Nancy E now owns 23,295 shares of the company’s stock valued at $3,628,000 after acquiring an additional 155 shares during the last quarter. Waverly Advisors LLC boosted its holdings in Johnson & Johnson by 153.3% in the third quarter. Waverly Advisors LLC now owns 53,016 shares of the company’s stock worth $8,257,000 after acquiring an additional 32,084 shares in the last quarter. United Services Automobile Association grew its stake in Johnson & Johnson by 0.5% in the third quarter. United Services Automobile Association now owns 691,445 shares of the company’s stock valued at $107,693,000 after acquiring an additional 3,522 shares during the period. First Business Financial Services Inc. grew its position in Johnson & Johnson by 2.8% in the 3rd quarter. First Business Financial Services Inc. now owns 10,723 shares of the company’s stock worth $1,670,000 after purchasing an additional 287 shares in the last quarter. Finally, Fusion Capital LLC boosted its stake in shares of Johnson & Johnson by 5.9% in the 3rd quarter. Fusion Capital LLC now owns 32,453 shares of the company’s stock worth $5,055,000 after buying an additional 1,800 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of recent research reports. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price target for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. The Goldman Sachs Group assumed coverage on shares of Johnson & Johnson in a research note on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price target for the company. Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Bank of America lowered their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Thursday, June 20th. Eight equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $174.07.

Johnson & Johnson Trading Up 0.3 %

Shares of JNJ stock opened at $146.18 on Friday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The firm has a fifty day moving average price of $148.17 and a 200-day moving average price of $154.19. The company has a market cap of $351.81 billion, a price-to-earnings ratio of 9.09, a PEG ratio of 2.44 and a beta of 0.53. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.68 earnings per share. As a group, equities analysts predict that Johnson & Johnson will post 10.62 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were issued a $1.24 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date was Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.39%. Johnson & Johnson’s payout ratio is presently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.